HumanOptics AG: Capital increase from authorized capital with subscription rights excluded against cash contribution planned; sustainable strengthening of equity capital basis

HumanOptics AG / Key word(s): Capital Increase
HumanOptics AG: Capital increase from authorized capital with subscription rights excluded against cash contribution planned; sustainable strengthening of equity capital basis

18-March-2020 / 14:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Capital increase from authorized capital with subscription rights excluded against cash contribution planned; sustainable strengthening of equity capital basis

Erlangen, 18 March 2020 - HumanOptics AG (the "Company") and its majority shareholder HumanOptics Holding AG with its registered office in Frankfurt am Main today agreed to carry out a capital increase from the authorized capital against cash contribution under exclusion of subscription rights in order to strengthen equity capital in the long term.

The Company's share capital of currently EUR 3,240,000.00 is to be increased by a nominal amount of EUR 247,280.00 against cash contribution to EUR 3,487,280,00 by issuing 247,280 new bearer shares with a proportionate amount of the share capital of EUR 1.00 per new share. The 247,280 new shares shall be subscribed exclusively by the majority shareholder HumanOptics Holding AG. The subscription rights of the shareholders shall be excluded pursuant to sections 203 (1) sentence 1, 186 (3) sentence 4 of the German Stock Corporation Act (Aktiengesetz). The placement price shall be EUR 10.11. This matches with the average closing price (arithmetic middle) of the HumanOptics share in trading on the Frankfurt Stock Exchange on the five trading days in the period from 11 March 2020 to 17 March 2020 in the amount of EUR 10.11 and is above the closing price of 17 March.

The capital increase serves to finance and strengthen the equity capital basis of the Company for the successful implementation of the growth strategy.
 

Contact:

HumanOptics AG
Investor Relations
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0) 9131 50665-0
E-Mail: IR@humanoptics.com

18-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de